Gastroparesis is currently the highest-volume condition in active GLP-1 federal litigation. A master complaint has been filed alleging Novo Nordisk and Eli Lilly knew about this risk and failed to warn patients adequately. FDA adverse event reports show over 500 deaths linked to semaglutide.
Warning: If you were hospitalized visited the ER or received a gastroparesis diagnosis while taking any GLP-1 medication you may have a valid legal claim. Statute of limitations deadlines apply — do not wait.
Gastroparesis is a condition in which the stomach muscles lose their ability to contract normally and push food through the digestive tract. The stomach becomes essentially paralyzed — food sits in it for hours or days rather than moving into the small intestine. This leads to severe nausea persistent vomiting dangerous malnutrition and in serious cases dehydration requiring hospitalization and IV nutrition.
GLP-1 receptor agonist medications like semaglutide work in part by slowing down gastric emptying — this is a built-in feature of how these drugs work. By slowing how quickly the stomach empties GLP-1 drugs reduce post-meal blood sugar spikes and create a feeling of fullness that reduces appetite. The problem is that in a significant subset of patients this slowing effect progresses to full gastroparesis — a serious medical condition that can persist long after the medication is discontinued and in some patients becomes permanent.
The FDA Adverse Event Reporting System has received hundreds of reports of deaths linked to semaglutide medications. The master complaint filed in the MDL alleges that Novo Nordisk and Eli Lilly were aware through their own clinical trial data that GLP-1 medications carried a meaningful risk of severe gastrointestinal harm yet marketed these medications to millions of patients without adequate disclosure of this risk.
The lawsuits are based on the failure to warn doctrine within product liability law. Drug manufacturers are required by law to disclose all known material risks to prescribing physicians. The master complaint alleges Novo Nordisk and Eli Lilly had access to significant data demonstrating gastroparesis risk and chose not to strengthen their warnings because doing so would have materially impacted the commercial success of their blockbuster drugs.
Even if you do not currently have all of these documents a legal team can assist you in obtaining them. Not having paperwork on hand does not disqualify you from having your case reviewed. What matters is that the records exist — and if you were hospitalized they almost certainly do.
90 seconds. No cost. No obligation. A specialist contacts you within 24 hours.